全文获取类型
收费全文 | 1591篇 |
免费 | 102篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 54篇 |
儿科学 | 51篇 |
妇产科学 | 32篇 |
基础医学 | 234篇 |
口腔科学 | 47篇 |
临床医学 | 135篇 |
内科学 | 266篇 |
皮肤病学 | 18篇 |
神经病学 | 194篇 |
特种医学 | 67篇 |
外科学 | 201篇 |
综合类 | 6篇 |
一般理论 | 2篇 |
预防医学 | 133篇 |
眼科学 | 62篇 |
药学 | 114篇 |
肿瘤学 | 87篇 |
出版年
2023年 | 5篇 |
2022年 | 12篇 |
2021年 | 34篇 |
2020年 | 36篇 |
2019年 | 25篇 |
2018年 | 29篇 |
2017年 | 38篇 |
2016年 | 44篇 |
2015年 | 33篇 |
2014年 | 46篇 |
2013年 | 72篇 |
2012年 | 105篇 |
2011年 | 99篇 |
2010年 | 82篇 |
2009年 | 76篇 |
2008年 | 107篇 |
2007年 | 97篇 |
2006年 | 97篇 |
2005年 | 94篇 |
2004年 | 94篇 |
2003年 | 88篇 |
2002年 | 74篇 |
2001年 | 25篇 |
2000年 | 17篇 |
1999年 | 23篇 |
1998年 | 11篇 |
1997年 | 11篇 |
1996年 | 12篇 |
1995年 | 11篇 |
1994年 | 10篇 |
1993年 | 9篇 |
1992年 | 11篇 |
1991年 | 10篇 |
1990年 | 9篇 |
1989年 | 5篇 |
1988年 | 8篇 |
1987年 | 7篇 |
1986年 | 7篇 |
1985年 | 6篇 |
1983年 | 5篇 |
1981年 | 6篇 |
1980年 | 11篇 |
1979年 | 9篇 |
1978年 | 5篇 |
1977年 | 5篇 |
1973年 | 5篇 |
1972年 | 8篇 |
1956年 | 4篇 |
1955年 | 5篇 |
1925年 | 5篇 |
排序方式: 共有1703条查询结果,搜索用时 15 毫秒
1.
Bergner Raoul; Hoffmann Martin; Riedel Klaus-Dieter; Mikus Gerd; Henrich Dirk M.; Haefeli Walter E.; Uppenkamp Michael; Walter-Sack Ingeborg 《Nephrology, dialysis, transplantation》2006,21(4):1019-1023
To cover intermediate sensitive Candida glabrata in ICU patients,fluconazole plasma peak levels at least in the range of 1632µg/ml appear necessary for treatment. Previous studiesdid not reach these fluconazole levels under continuous veno-venoushaemofiltration (CVVHF) with dosages of 200600 mg fluconzoledaily. In the present study, nine patients simultaneously requiringCVVHF for treatment of acute oligoanuric renal failure and antimycotictherapy of Candida septicemia received fluconazole 800 mg/day.Fluconazole plasma levels were determined to evaluate whetherthis dosage is adequate to reach the advised fluconazole levels.Patients were dialysed on two consecutive days with an ultrafiltrationrate (UF) of 1000 ml/h or 2000 ml/h, respectively, in a randomizedorder. The predilution was 800 ml/h and 1800 ml/h, respectively.The treatment was tolerated without adverse effects. All patientsreached plasma fluconazole concentrations between 16 and 32µg/ml, remaining in this range for a minimum of 1 up to24 h with a mean of 9.6 h and a UF rate of 2000 ml/h, and 15.7h with a UF rate of 1000 ml/h. So far, there are no in vivodata on the fluconazole plasma concentrations required for effectivetreatment. However, our data demonstrate, that at least thefluconazole concentrations desirable on the basis of in vitrosusceptibility testing can be reached in critically ill patientson CVVHF in an ICU setting. However, in these patients, 800mg fluconazole/day are necessary to achieve fungicidal drugconcentrations. 相似文献
2.
3.
4.
5.
Sequential 99mTc-hydrazinonicotinamide-annexin V imaging for predicting response to chemotherapy. 总被引:1,自引:0,他引:1
Sylvie Rottey Guido Slegers Simon Van Belle Ingeborg Goethals Christophe Van de Wiele 《Journal of nuclear medicine》2006,47(11):1813-1818
This study was undertaken to evaluate changes in relative (99m)Tc-hydrazinonicotinamide (HYNIC)-annexin V tumor uptake over time in patients undergoing chemotherapeutic treatment at baseline and at 5-7 h and 40-44 h after treatment initiation. Imaging results are related to clinical outcomes, as assessed with response evaluation criteria in solid tumors (RECIST). METHODS: We prospectively included 20 patients (11 men and 9 women; mean age, 59.8 y; range, 22-75 y) scheduled for chemotherapy (n = 19) or bisphosphonate treatment (n = 1). Curable disease was present in 5 patients. The other patients had metastatic disease and were treated in a palliative setting. Three of the 20 enrolled patients were excluded from analysis: 1 patient ultimately refused the proposed chemotherapy treatment; because of difficulties with the labeling procedure, 1 patient did not receive a pretreatment scan; and 1 patient presented with an allergic reaction (rash and nausea) to the (99m)Tc-HYNIC-annexin V formulation. The remaining 17 patients underwent 3 scintigraphic scans with (99m)Tc-HYNIC-annexin V: before treatment and 5-7 h and 40-44 h after treatment initiation. The tumor response was evaluated with RECIST and related to observed changes in the ratios of tumor activity to background activity for the largest known lesion; values exceeding 25% the baseline value on either the 5- to 7-h scan or the 40- to 44-h scan were considered significant. RESULTS: With the proposed sequential imaging protocol and a 25% change threshold, responders to treatment could be separated from nonresponders with a 94% accuracy (16/17 patients). CONCLUSION: Sequential (99m)Tc-HYNIC-annexin V imaging may allow for assessment of the response to chemotherapy within 3 d after treatment initiation. 相似文献
6.
The association between nitrate levels in public and private sources of drinking water and gastric cancer mortality in Wisconsin was investigated in a case-control study. All gastric cancer deaths of Wisconsin residents from 1982 through 1985 were compared with deaths from other causes (controls), and nitrate levels in the home drinking water of these residents were determined. Nitrate measures for public sources were obtained from historic nitrate data from municipal sources that existed in 1970. Nitrate measures for private water sources were obtained by testing the wells individually at the existing residences. Controls were matched individually to gastric cancer cases with respect to sex, year of birth, year of death, Wisconsin birth, and Wisconsin residency at the time of death. Matched-pair analyses were performed on the paired data, and the following levels of nitrate-nitrogen exposure were used as indicators of exposure: 0.5, 2.5, 5.0, and 10.0 mg/l. Matched-pair analysis was also performed for which private water supply constituted exposure. Odds ratios and 95% confidence intervals were, respectively, 0.92 (0.75, 1.12); 0.97 (0.74, 1.35); 0.86 (0.69, 1.08); 1.50 (0.12, 18.25); and 1.09 (0.82, 1.47) for exposure to private well-water sources. These results did not indicate an increased risk of gastric cancer at any level. 相似文献
7.
N. Zöllner Ingeborg Walter-Saok M. M. Kochen 《Journal of molecular medicine (Berlin, Germany)》1987,65(1):33-26
Ohne Zusammenfassung 相似文献
8.
9.
Ingeborg S. Aaberge Philipp Oster Oddveig S. Helland Anne-Cathrine Kristoffersen Ellen Ypma E. Arne H?iby Berit Feiring Hanne N?kleby 《Clinical and Vaccine Immunology : CVI》2005,12(5):599-605
MenBvac and Menjugate are safe and efficacious vaccines. The purpose of this study was to evaluate safety and immunogenicity of the combination (MenB/C) of the lyophilized active components of the conjugated group C vaccine Menjugate when reconstituted with the full liquid group B outer membrane vesicle vaccine MenBvac compared to MenBvac and Menjugate given separately. At 6-week intervals, healthy adults were given one dose of MenB/C followed by two doses of MenBvac (MenB/C group), three doses of MenBvac (MenB group), or one dose of Menjugate and two doses of placebo (MenC group). Injection site reactions were frequent in all groups. However, most reactions were short lasting and mild or moderate in intensity, and the vaccines were found to be well tolerated, with no vaccine-related serious adverse events. MenB/C was immunogenic with regard to both serogroup B and C meningococci. Both the serum bactericidal assay and the enzyme-linked immunosorbent assay analyses showed that the immune responses of the combination vaccine were similar to the immune responses of its separate components MenBvac and Menjugate for both serogroup B and C. In conclusion, the combined MenB/C vaccine is safe and immunogenic. The two vaccines do not interact negatively with each other and can easily be administered in the same syringe. The induced immune responses suggest that the combined vaccine is likely to confer protection against systemic group B disease caused by the vaccine strain as well as against group C meningococcal disease. 相似文献
10.